INNOVENT BIOLOGICS, INC.

Insiders Innovent Biologics, Inc.

Equities

1801

KYG4818G1010

Delayed Hong Kong S.E. Other stock markets 01:18:11 13/05/2024 pm IST			5-day change	1st Jan Change
39.5 ^HKD	-4.59%		-3.18%	-7.37%

07/05	Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer	CI
30/04	Innovent Biologics, Inc. Reports Revenue Results for the First Quarter of 2024	CI

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer	30/04	CI
Innovent Appoints Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer	17/04	CI
Innovent Biologics, Inc. Announces Appointment of Shun Lu as Independent Non-Executive Director and A Member of the Strategy Committee	09/02	CI
Innovent Biologics Names New CFO	05/02	MT
Innovent Appoints Gary Zieziula as Independent Non-Executive Director	01/22/01	CI
Innovent Biologics, Inc. Announces Executive Changes	25/22/25	CI
Innovent Announces the Establishment of the Scientific Advisory Board	09/21/09	CI
Innovent Biologics, Inc. Announces the Appointment of Dr. Yong Jun Liu as the President of the Group	15/20/15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW